- Home
- LVTX vs GBIO Comparison
LVTX vs GBIO Comparison
Compare LVTX & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- GBIO
- Stock Information
- Founded
- LVTX 2016
- GBIO 2016
- Country
- LVTX Netherlands
- GBIO United States
- Employees
- LVTX N/A
- GBIO N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- LVTX Health Care
- GBIO Health Care
- Exchange
- LVTX Nasdaq
- GBIO Nasdaq
- Market Cap
- LVTX 33.9M
- GBIO 29.5M
- IPO Year
- LVTX 2021
- GBIO 2020
- Fundamental
- Price
- LVTX $1.43
- GBIO $4.61
- Analyst Decision
- LVTX Hold
- GBIO Strong Buy
- Analyst Count
- LVTX 3
- GBIO 4
- Target Price
- LVTX $1.75
- GBIO $73.33
- AVG Volume (30 Days)
- LVTX 30.6K
- GBIO 250.6K
- Earning Date
- LVTX 08-19-2025
- GBIO 08-06-2025
- Dividend Yield
- LVTX N/A
- GBIO N/A
- EPS Growth
- LVTX N/A
- GBIO N/A
- EPS
- LVTX N/A
- GBIO N/A
- Revenue
- LVTX $4,990,000.00
- GBIO $24,556,000.00
- Revenue This Year
- LVTX N/A
- GBIO N/A
- Revenue Next Year
- LVTX N/A
- GBIO N/A
- P/E Ratio
- LVTX N/A
- GBIO N/A
- Revenue Growth
- LVTX N/A
- GBIO 146.47
- 52 Week Low
- LVTX $0.85
- GBIO $3.00
- 52 Week High
- LVTX $2.21
- GBIO $36.50
- Technical
- Relative Strength Index (RSI)
- LVTX 58.31
- GBIO 56.74
- Support Level
- LVTX $1.40
- GBIO $4.05
- Resistance Level
- LVTX $1.67
- GBIO $5.00
- Average True Range (ATR)
- LVTX 0.10
- GBIO 0.57
- MACD
- LVTX 0.00
- GBIO 0.04
- Stochastic Oscillator
- LVTX 33.33
- GBIO 50.38
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.